Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ).
Shanghai HeartCare Medical Technology Corporation Limited has announced its intention to abolish its Supervisory Committee in favor of establishing an Audit Committee, in compliance with the new amendments to the Company Law of the People’s Republic of China effective July 1, 2024. This move is part of a broader effort to enhance corporate governance and align with updated regulatory requirements, which also includes proposed amendments to the company’s Articles of Association. These changes are subject to shareholder approval at an upcoming extraordinary general meeting.
The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a company incorporated in the People’s Republic of China, operating in the medical technology industry. It is listed on the Stock Exchange of Hong Kong and focuses on providing innovative medical solutions.
Average Trading Volume: 66,761
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.77B
For a thorough assessment of 6609 stock, go to TipRanks’ Stock Analysis page.